Review on monogenic diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 4, 2011, Pages 252-258

  Steck, Andrea K ^a   Winter, Wiliam E ^b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Maturity onset diabetes of the young; monogenic diabetes; neonatal diabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOKINASE; GLUCOSE; GLYCOLYTIC ENZYME; HEPATOCYTE NUCLEAR FACTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1BETA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; KRUPPEL LIKE FACTOR; NEUROGENIC DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; SOMATOSTATIN; SULFONYLUREA; SULFONYLUREA RECEPTOR 1; TRANSCRIPTION FACTOR FOXP3; ZINC FINGER PROTEIN;

AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CEREBELLUM HYPOPLASIA; CHROMOSOME 6Q; CHROMOSOME ABERRATION; CLINICAL FEATURE; CONGENITAL HYPOTHYROIDISM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG MEGADOSE; DYSLIPIDEMIA; EMBRYO DEVELOPMENT; GENE MUTATION; GENETIC ASSOCIATION; GENITAL MALFORMATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERURICEMIA; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY POLYCYSTIC DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LOW DRUG DOSE; MACROGLOSSIA; MACROSOMIA; MATERNAL DISEASE; MATERNAL HYPERGLYCEMIA; MATURITY ONSET DIABETES MELLITUS; NEWBORN DIABETES MELLITUS; ONSET AGE; OSTEOPENIA; PROTEIN EXPRESSION; REVIEW; SPONDYLOEPIPHYSEAL DYSPLASIA; UMBILICAL HERNIA;

ANIMALS; DIABETES MELLITUS, TYPE 1; GENOTYPE; GLUCOKINASE; HLA-DR3 ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; INSULIN-SECRETING CELLS; PHENOTYPE; TRANSCRIPTION FACTORS;

EID: 79960773539     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283488275     Document Type: Review

References (64)

1. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical patho-physiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345:971-980.
2. Hattersley A, Bruining J, Shield J, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009; 10 (Suppl 12):33-42.
3. Stride A, Hattersley AT. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med 2002; 34:207-216. (Pubitemid 34804194)
4. Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetol 2008; 51:546-553.
5. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008; 4:200-213. (Pubitemid 351430925)
6. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838-1849. (Pubitemid 38917250)
7. Greeley SA, Tucker SE, Worrell HI, et al. Update in neonatal diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17:13-19.
8. Temple IK, Gardner RJ, Mackay DJ, et al. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diab 2000; 49:1359-1366. (Pubitemid 30624238)
9. Shepherd M, Shields B, Ellard S, et al. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009; 26:437-441.
10. Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus [see comments]. N Engl J Med 1993; 328:697-702. (Pubitemid 23073372)
11. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009; 30:1512-1526.
12. Gloyn AL. Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 2003; 22:353-362. (Pubitemid 37346107)
13. Lorini R, Klersy C, d'Annunzio G, et al. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diab care 2009; 32:1864-1866.
14. Solera J,Arias P, Aminoso C, et al. Identification ofeight new mutations in the GCK gene by DHPLC screening in a Spanish population. Diabetes Res Clin Pract 2009; 85:20-23.
15. Fajans SS, Bell GI. Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees. Diabetol 2006; 49:1106-1108.
16. Cuesta-Munoz AL, Tuomi T, Cobo-Vuilleumier N, et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY). Diab care 2010; 33:290-292.
17. Hattersley AT, Pearson ER. Mini review: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology 2006; 147:2657-2663. (Pubitemid 43764600)
18. Spyer G, Mac Leod KM, Shepherd M, et al. Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet Med 2009; 26:14-18.
19. Cereghini S. Liver-enriched transcription factors and hepatocyte differentia-tion.FASEBJ 1996; 10:267-282. (Pubitemid 26079946)
20. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A 1997; 94:13209-13214. (Pubitemid 27518501)
21. Wang H, Maechler P, Antinozzi PA, et al. Hepatocyte nuclear factor 4alpha regulates the expression of pancreatic beta -cell genes implicated in glucose metabolism and nutrient-induced insulin secretion. J Biol Chem 2000; 275:35953-35959.
22. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, et al. Transcriptional regulation of human apolipoprotein genes Apo B, Apo CIII, and Apo AII by membersof the steroid hormone receptorsuperfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 1992; 267:15849-15860.
23. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat 2006; 27:854-869. (Pubitemid 44336935)
24. Cappelli A, Tumini S, Consoli A, et al. Novel mutations in GCK and HNF1A genes in Italian families with MODY phenotype. Diabetes Res Clin Pract 2009; 83:e72-e74.
25. Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hypergly-caemia and response to treatment in diabetes. Lancet 2003; 362:1275-1281. (Pubitemid 37324255)
26. Pearson ER, Pruhova S, Tack CJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha muta-tions in a large European collection. Diabetol 2005; 48:878-885. (Pubitemid 40767980)
27. Frayling TM, Evans JC, Bulman MP, et al. beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diab 2001; 50 (Suppl 1):S94-S100. (Pubitemid 32148228)
28. Owen KR, Thanabalasingham G, James TJ, et al. Assessment of high-sensi-tivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diab care 2010; 33:1919-1924.
29. Bellanne-Chantelot C, Clauin S, Chauveau D, et al. Largegenomic rearrange-ments in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diab 2005; 54:3126-3132. (Pubitemid 43334365)
30. Bingham C, Hattersley AT. Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. Nephrol Dial Transplant 2004; 19:2703-2708. (Pubitemid 39480961)
31. Pearson ER, Badman MK, Lockwood CR, et al. Contrasting diabetes phe-notypes associated with hepatocyte nuclear factor-1alpha and -1beta muta-tions. Diab Care 2004; 27:1102-1107. (Pubitemid 38579773)
32. Bellanne-Chantelot C, Chauveau D, Gautier JF, et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 2004; 140:510-517.
33. St-Onge L, Wehr R, Gruss P. Pancreas development and diabetes. Curr Opin Genet Dev 1999; 9:295-300. (Pubitemid 29286469)
34. Naya FJ, Huang HP, Qiu Y, et al. Diabetes, defective pancreatic morphogen-esis, and abnormal enteroendocrine differentiation in BETA2/neuro D-deficient mice. Genes Dev 1997; 11:2323-2334. (Pubitemid 27408530)
35. Kristinsson SY, Thorolfsdottir ET, Talseth B, et al. MODY in Iceland is associated with mutations in HNF-1alpha and a novel mutation in Neuro D1. Diabetol 2001; 44:2098-2103. (Pubitemid 33124057)
36. Fernandez-Zapico ME, van Velkinburgh JC, Gutierrez-Aguilar R, et al. MODY7 gene, KLF11, is a novel p300-dependent regulator of Pdx-1 (MODY4) transcription in pancreatic islet beta cells. J Biol Chem 2009; 284:36482-36490.
37. Torsvik J, Johansson S, Johansen A, et al. Mutations in the VNTR of the carboxyl-ester lipase gene (CEL) are a rare cause of monogenic diabetes. Hum Genet 2010; 127:55-64.
38. Raeder H, Johansson S, Holm PI, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet 2006; 38:54-62. (Pubitemid 43011882)
39. Vesterhus M, Raeder H, Aurlien H, et al. Neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to CEL mutations. Diab Care 2008; 31:1738-1740.
40. Rubio-Cabezas O, Edghill EL, Argente J, Hattersley AT. Testing for mono-genic diabetes among children and adolescents with antibody-negative clinically defined type 1 diabetes. Diabet Med 2009; 26:1070-1074.
41. Bonfanti R, Colombo C, Nocerino V, et al. Insulin gene mutations as cause of diabetes in children negative for five type 1 diabetes autoantibodies. Diab Care 2009; 32:123-125.
42. Boesgaard TW, Pruhova S, Andersson EA, et al. Further evidence that mutations in INS can be a rare cause of maturity-onset diabetes oftheyoung (MODY). BMC Med Genet 2010; 11:42.
43. Borowiec M, Liew CW, Thompson R, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A 2009; 106:14460-14465.
44. Plengvidhya N, Kooptiwut S, Songtawee N, et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab 2007; 92:2821-2826. (Pubitemid 47037395)
45. Edghill EL, Minton JA, Groves CJ, et al. Sequencing of candidate genes selected by beta cell experts in monogenic diabetes of unknown aetiology. JOP 2010; 11:14-17.
46. Guilar-Bryan L, Bryan J. Neonatal diabetes mellitus. Endocr Rev2008;29:265-291. (Pubitemid 351679699)
47. Wiedemann B, Schober E, Waldhoer T, et al. Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register. Pediatr Diabetes 2010; 11:18-23.
48. Slingerland AS, Shields BM, Flanagan SE, et al. Referral rates for diagnostic testing supportan incidenceof permanent neonataldiabetesin three European countries of at least 1 in 260,000 live births. Diabetol 2009; 52:1683-1685.
49. Gardner RJ, Robinson DO, Lamont L, et al. Paternal uniparental disomy of chromosome 6 and transient neonatal diabetes mellitus. Clin Genet 1998; 54:522-525. (Pubitemid 29002417)
50. Hermann R, Laine AP, Johansson C, et al. Transient but not permanent neonatal diabetes mellitus is associated with paternal uniparental isodisomy of chromosome 6. Peds 2000; 105 (1 Pt 1):49-52. (Pubitemid 30035717)
51. Cave H, Polak M, Drunat S, et al. Refinement of the 6q chromosomal region implicated in transient neonatal diabetes. Diab 2000; 49:108-113. (Pubitemid 30022931)
52. Gardner RJ, Mackay DJ, Mungall AJ, et al.An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet 2000; 9:589-596. (Pubitemid 30154017)
53. Varrault A, Ciani E, Apiou F, et al. h ZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. Proc Natl Acad Sci U S A 1998; 95:8835-8840.
54. Mackay DJ, Callaway JL, Marks SM, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008; 40:949-951.
55. Babenko AP, Polak M, Cave H, et al.Activating mutations inthe ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456-466. (Pubitemid 44162273)
56. Shimomura K. The K(ATP) channel and neonatal diabetes. Endocr J 2009; 56:165-175.
57. Stoy J, Greeley SA, Paz VP, et al. Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr Diabetes 2008; 9:450-459.
58. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diab 2005; 54:2503-2513. (Pubitemid 41233571)
59. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467-477. (Pubitemid 44162274)
60. Koster JC, Cadario F, Peruzzi C, et al. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 2008; 93:1054-1061. (Pubitemid 351398592)
61. Slingerland AS, Nuboer R, Hadders-Algra M, et al. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59 M mutation in the KCNJ11 gene. Diabetol 2006; 49:2559-2563.
62. Rafiq M, Flanagan SE, Patch AM, et al. Effective treatment with oral sulfo-nylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diab Care 2008; 31:204-209. (Pubitemid 351213320)
63. Stoy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A 2007; 104:15040-15044. (Pubitemid 47619589)
64. Polak M, Dechaume A,Cave H, et al. Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group. Diab 2008; 57:1115-1119.